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Effect of a specific endothelin A receptor antagonist on marine lupus
nephritis. The present study was designed to assess whether a specific
endothelin A (ETA) receptor antagonist, FR139317, affects the progres-
sion of lupus ncphritis and affects transcription of mRNA for extracellular
matrix (ECM) components, metalloproteinases (MMPs) and tissue inhib-
itor of metalloproteinase (TIMP)-l, and accumulation of ECM proteins in
the renal cortex of NZB/W Fl mice. mRNA levels for al(I), al(III),
al (IV) collagen chains, laminin Bi and B2 chains, heparan sulfate
proteoglycan (HSPG), MMP-1, -2, -3, and TIMP-1 increased significantly
as nephritis progressed in NZB/W Fl mice. At 48 weeks of age, the levels
of mRNA for al(I), al(III), al(IV) collagen chains, laminin Bi and B2
chains, HSPG, MMP-1, -2, -3, and TIMP-1 were increased by 5.6- (P C
0.001), 3.6- (P < 0.01), 6.8- (P cc 0.001), 5.2- (P cc 0.001), 5.0- (P cc 0.001),
6.0- (P cc 0.001), 7.6- (P cc 0.001), 4.2- (P cc 0.01), 8.2- (P cc 0.001), and
15.2-fold (P cc 0.001), respectively, in the renal cortex of NZB/W Fl mice
compared to NZW mice. Immunofiuorescence microscopy showed that
the accumulation of collagens I, III, and IV, laminin, and HSPG in the
renal cortex of NZB/W Ft mice increased markedly with the progression
of nephritis. At 20 weeks of age, NZB/W Fl and NZW mice were divided
into two groups that received either FR139317 or its vehicle (saline)
intraperitoneally, daily, for 28 weeks. The development of histological
lesions, proteinuria, hypertension, accumulation of collagens I, III, and
IV, laminin, and HSPG in the renal cortex of NZBIW Fl mice were
suppressed by FR139317 treatment. Levels of mRNA for ECM compo-
nents, MMPs, and TIMP-1 in the renal cortex of NZB/W Fl mice were
ameliorated significantly by FR139317 administration. There data suggest
that FR139317 treatment can be used therapeutically to regulate the
expression of ECM components, MMPs, and TIMP-1 in murine lupus
nephritis.
Lupus nephritis is an immune complex glomerulonephritis
which varies in histology from mild mesangial deposits to a
full-blown diffuse proliferative glomerulonephritis [1]. NZB/W Ft
female mice have been used extensively as a model of lupus
nephritis [2]. We reported previously that the expression of
mRNA for ECM components, metalloproteinases (MMP5), and
tissue inhibitor of metalloproteinase (TIMP)-1 is increased in the
renal cortex of NZB/W Fl mice [3, 4]. These data suggest that
abnormal expression of mRNA for MMPs and TIMP-1 may
contribute to the evolution of glomerular injury in lupus nephritis
and/or may be involved in the extensive ECM remodeling that
accompanies lupus nephritis. Recently, we documented the up-
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gene expression in NZB/W Fl mice [5]. ETs contribute to the
progression of glomerular disease either by inducing a local
vasoconstriction or by stimulating mesangial cell proliferation and
excessive synthesis of ECM components [6, 7]. Most recently,
some investigators have reported that ETA receptor antagonist
may be important in preventing acute renal failure or glomerular
sclerosis [8, 9].
The present study was designed to investigate whether
FR139317 prevented the renal injury in NZB/W Fl mice, and
whether this compound attenuated ECM accumulation and the
abnormally high mRNA expression of ECM components, MMPs,
and TIMP-l in the renal cortex of NZB/W Fl mice.
Methods
Animals
Two hundred six-week-old female NZB/W Fl mice and 100
age-matched NZW mice were obtained from Charles River, Inc.
(Atsugi, Kanagawa, Japan) and maintained at the mouse unit of
Juntendo University on standard laboratory chow. Ten mice from
each strain were killed by cervical dislocation at 8, 32, or 48 weeks
after birth. The kidneys were removed immediately from the
surrounding peritoneal fat and were sectioned longitudinally. At
20 weeks of age (just before nephritis developed), NZB/W Fl
mice and NZW mice were assigned randomly to a treated or
untreated group. We injected NZB/W Fl mice and NZW mice
intraperitoneally with the specific ETA receptor antagonist,
FR139317 (Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan) [8,
10] daily at a dose of 3.2 mg/100 g for 28 weeks. FR139317
specifically binds ETA receptor binding sites, as documented in
vitro by concentration-dependent inhibition of the binding of
labeled ET-1 to porcine and human aortic microsomes with an
IC50 in the nanomolar range [11]. In vivo a single bolus dose of
FR139317 completely inhibited the pressor response to ET-1, but
had no effect on the initial depressor response due to ET-3 in
conscious normotensive rats [11]. Untreated NZB/W Fl mice and
NZW mice were injected daily with saline for 28 weeks. The
cortex of the sectioned kidney was either frozen rapidly in liquid
nitrogen for immunohistochemistry and RNA extraction of the
cortex or fixed for light microscopy. Freshly voided urine speci-
mens from each animal was tested with standard uropaper (Eiken
Chemical Co., Tokyo, Japan) at 8, 32, and 48 weeks of age.
Animals were considered to have developed proteinuria when
their urinary protein concentration exceeded 300 mg/dl (3+)
[3,4].
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Renal function
Glomerular filtration rate (GFR) was measured as the clear-
ance of inulin as described by Kiberd [1, 12]. C14 inulin-loaded (50
sCi) osmotic minipumps were placed intraperitoneally under
pentobarbital anesthesia. Twenty-four hours later, ten consecutive
24-hour urine collections were begun, with plasma samples taken
by retro-orbital puncture bracketing the urine collections. Urine
and plasma C14 was measured by scintillation spectrometry. GFR
was calculated from urine and plasma C14 counts and urine flow
rates.
Blood pressure measurement
Indirect systolic blood pressure was measured with a photoelec-
tric tail cuff connected to a pulse amplifier and manometer [13].
The unanesthetized mice were placed in plastic holders, and their
tails were warmed with a floodlight while their bodies were
shielded with aluminum foil.
Light microscopic studies
For light microscopic examination, the renal tissues were fixed
in 10% buffered formalin and embedded in paraffin. Renal
sections (4 tim) were stained with hematoxylin and eosin and
periodic acid-Schiff. For each specimen (10 mice), 30 glomeruli
were examined and the histopathology was graded arbitrarily
graded according to the following criteria [14]: 0, normal; 1+,
mild mesangial cell and matrix proliferation; 2+, more extensive
mesangial proliferation; 3+, diffuse glomerular proliferation with
basement membrane thickening; and 4+, all of the above changes
associated with wire loop lesions, glomerular sclerosis, and inter-
stitial fibrosis. In addition, we scored the degree of interstitial
nephritis [15]. Mononuclear cell infiltrates around renal arteries
were graded on a scale of 0 to 4+: 0, no lymphocytes; 1, few
lymphocytes; 2, lymphocytes surrounding 25% to 50% of the
arterial wall; 3, lymphocytes surrounding 75% of the arterial wall;
and 4, lymphocytes surrounding the entire artery.
Immunohistochemical studies
Immunofluorescence staining of renal tissues was performed by
our previously described method [16]. In brief, renal cryostat
sections were stained with fluorescein isothiocyanate (FITC)-
conjugated rabbit anti-mouse gamma G immunoglobulin (IgG),
1gM, C3 (Cappel Laboratories, Malvern, PA, USA) (1:32). Rabbit
antibodies to mouse laminin, collagen IV, and HSPG, prepared as
described previously [17, 18] (1:16), were provided by Drs. Hynda
Kleinman and John Hassell, National Institute of Dental Re-
search (Bethesda, MD, USA). Monospecific antibodies raised
against rat type I and III collagens were provided by Dr. Akira
Ooshima, Wakayama Medical College (Wakayama, Japan) [19]
(1:16). Fluorescein isothiocyanate-conjugated goat anti-rabbit
IgG was purchased from Cappel Laboratories. Renal sections (4
were incubated with various antibodies after the second
incubation with FITC-conjugated anti-rabbit IgG antibodies. The
relative amount of staining was scored semiquantitatively from 0
to 5: 0, no staining; 1, trace staining; 2, slight staining; 3, moderate
staining; 4, intense staining; and 5, most intense staining. The
scores were calculated by averaging the staining score in 20
glomeruli in each group of 10 mice. In addition, the scores of types
I and III collagen were calculated in interstitial areas in 10 mice.
Extraction and quantitation of cellular RNA
The renal cortices were separated from medulla from 10
NZB/W Fl mice and 10 NZW mice with or without FR139317
treatment, and frozen separately in liquid nitrogen for RNA
extraction at each time point. Total cellular RNA was extracted
from renal cortices by the acid guanidinium thiocyanate-phenol-
chloroform extraction method [20]. The total RNA concentration
was determined spectrophotometrically at 260 nm. The purity of
the RNA preparation was assessed by measuring the ratio of
absorbance at 260 to that at 280 nm. RNA samples (20 tg) were
denatured and electrophoresed through 0.7% agarose gels con-
taining 2.2 mol/liter formaldehyde and were then transferred by
capillary blotting onto nylon filters (GeneScreen, New England
Nuclear, Boston, MA, USA). Before transferring RNA onto nylon
membranes, ethidium-stained gels were visualized under ultravi-
olet illumination to determine the position of the 28S and 18S
ribosomal RNA bands so as to assess the integrity of the RNA,
and to verify that equal amounts of RNA were loaded in each
lane. The membrane was air-dried, then baked at 80° for two
hours. The membrane was hybridized at 65°C for 16 hours in 5X
SSC (1X SSC=0.15 mol/l NaC1, 0.015 mol/liter sodium citrate),
50% formamide, lx Denhardt's solution (0.02% polyvinylpyrro-
lidone, 0.02% Ficoll and 0.02% BSA) and 1% sodium dodecyl
sulfate (SDS) containing 100 g/ml denatured salmon sperm
DNA. The membrane was washed in 2X SSC at room tempera-
ture for five minutes, followed by 2X SSC containing 1% SDS at
65°C for 30 minutes, and 0.1X SSC at room temperature for
another 30 minutes. The filter was then exposed to Kodak
X-OMAT-AR film (Eastman-Kodak, Rochester, NY, USA) at
—70° with the aid of intensifying screens. Multiple exposures were
scanned with a Shimadzu CS-9000 densitometer (Shimadzu Man-
ufacturing, Kyoto, Japan) to determine the linear range.
cDNA probes
The cDNA probes used for Northern analysis were prepared as
follows. Clones for the al(IV) collagen chain (pFAC), laminin Bi
(p24) and B2 (p7) chains were isolated from a cDNA library
constructed from differentiated F9 teratocarcinoma cell mRNA,
as reported previously [21, 22]. Heparan sulfate proteoglycan
(clone 7), rat cvl(I) (paiRl) and al(III) (1.8 Kb EcoRl fragment)
collagen cDNA probes were provided by Dr. Yoshihiko Yamada,
National Institute of Dental Research [23—26]. Rat MMP-1 and
MMP-3 cDNA probes were provided by Dr. Lynn M. Matrisian,
Vanderbilt University (Nashville, TN, USA) [27, 28]. The cDNA
probe for human MMP-2 was provided by Dr. Gregory I. Gold-
berg and Barry L. Marmer, Washington University School of
Medicine (St. Louis, MO, USA) [29, 30]. Human TIMP-1 cDNA
was provided by Dr. Masanobu Naruto, Basic Research Labora-
tories, Toray Industries (Kanagawa, Japan) [31]. The rat GAPDH
cDNA was obtained from the American Type Culture Collection
(Rockville, MD, USA). The cDNA inserts were excised and
labeled using a random-primed cDNA labeling kit (Boehringer-
Mannheim-Yamanouchi K.K., Tokyo, Japan) with 32P-labeled
deoxynucleotides (New England Nuclear) to a specific activity of
iO cpm/sg [32].
Statistical analysis
The quantitative densitometric measurements on the Northern
blots were normalized to the signal for GAPDH mRNA. Values
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Table 1. Incidence of proteinuria in NZBIW Fl micc and NZW mice
Incidence of proteinuria %
48 weeks32 weeks
NZBIW Fl mice
Treated with FR139317 10 30
Untreated 30 80
NZW mice
Treated with FR139317 0 0
Untreated 0 0
Animals were considered to have developed proteinuria when the
urinary protein concentration was more than 300 mg/dl (3+).
Table 2. Glomerular filtration rate in NZB/W Fl mice and NZW mice
32 weeks 48 weeks
jxl/min
NZB/W Fl mice
Treated with FR139317
Untreated
NZW mice
Treated with FR139317
Untreated
210 14
142 10
244 12
238 14
160 ioa
44 11
236 16
248 18
Values are means SE.
a P C 0.01 compared with untreated NZB/W Fl mice
are expressed as optical density units relative to the specific
mRNA level observed in mRNA from untreated NZW mice. All
values are expressed as a mean sri. Statistical significance was
determined by Student's t-test or one way analysis of variance with
modified t test performed using the Bonferroni correction [33].
Results
Survival
FR139317-treated NZBIW Fl mice survived much longer than
did untreated NZB/W Fl mice. The percentages of untreated
NZBIW Fl mice surviving were 60% at 32 weeks of age and 20%
at 48 weeks of age, whereas those of FR139317-treated NZB/W
Fl mice surviving were 90% at 32 weeks of age and 70% at 48
weeks of age. There was no significant difference in survival
between NZW mice and FR139317-treated NZW mice.
Proteinuria
Urinary protein excretion is shown in Table 1. In NZB/W Fl
mice, proteinuria began to appear at 24 weeks of age, and the
prevalence of proteinuria reached 30% of all animals at 32 weeks
of age and 80% at 48 weeks of age. The incidence of proteinuria
was significantly less in NZBIW Fl mice treated with FR139317
(32 weeks, 10%; 48 weeks, 30%). In contrast, none of the NZW
mice with or without FR139317 administration developed pro-
teinuria up to 48 weeks of age.
Renal function
The measured glomerular filtration rate (GFR) is presented in
Table 2. In NZB/W Fl mice, GFR fell significantly with age (8
weeks, 240 10 gl/min; 32 weeks, 142 10 i1/min; 48 weeks, 44
11 tl/min). FR139317 ameliorated the GFR in NZB/W Fl mice
(32 weeks, 210 14 j.rl/min; 48 weeks, 160 10 j.d/min). In NZW
Table 3. Blood pressure in NZB/W Fl mice and NZW mice
32 weeks 48 weeks
mmHg
NZB/W Fl mice
Treated with FR139317 98 6 128 ioa
Untreated 116 8 162 12
NZW mice
Treated with FR139317 84 5 88 7
Untreated 88 6 92 6
Values are means SE.
a P < 0.01 compared with untreated NZB/W Fl mice
mice with or without FR139317 administration, GFR showed little
change throughout the experimental periods (Table 2).
Blood pressure
The blood pressure is shown in Table 3. NZW mice with or
without FR139317 had no evidence of hypertension. The blood
pressure in NZB/W Fl mice increased with age (8 weeks, 84 5
mm Hg; 32 weeks, 116 8 mm Hg; 48 weeks, 162 12 mm Hg).
FR139317 reduced the increase in blood pressure (32 weeks, 98
6 mm Hg; 48 weeks, 128 10 mm Hg).
Light microscopy
No distinctive pathological changes were observed by light
microscopy in NZW mice treated with or without FR139317 up to
48 weeks of age. In untreated NZB/W Fl mice, proliferation of
glomerular cells and thickening of the mesangial matrix were
observed at 32 weeks of age. Glomerular lobulation, fibrinoid
necrosis, crescent formation, severe mesangial expansion and
glomerulosclerosis were observed at 48 weeks of age. The renal
tubules were also severely damaged and dilated with casts. A
striking feature was infiltration by mononuclear cells between
calices, and in the renal interstitium and surrounding blood
vessels. FR139317 ameliorated these histopathological changes,
including glomerular volume, mesangial proliferation and infiltra-
tion by mononuclear cells (Fig. 1). The histopathological scores of
NZB/W Fl mice and NZW mice with or without FR139317
treatment are shown in Table 4.
Immunofluorescence microscopy
No deposits of IgG, 1gM or C3 were detected in the glomeruli
of NZW mice regardless of FR139317 administration throughout
the experiments. IgG, 1gM, and C3 were deposited in the mesang-
ial areas of NZB/W Fl mice at 32 weeks of age. This deposition
was increased and extended to the glomerular capillary walls by 48
weeks of age. The amount of immunoreactants in the glomeruli
was decreased by treatment with FR139317.
At 32 weeks of age, thickened capillary loops, thickened tubular
basement membranes and expanded mesangial matrix showed
increased staining for type IV collagen, laminin, and HSPG in the
kidneys of NZB/W Fl mice. At 48 weeks of age, the distribution
and intensity of these components was increased significantly in
the glomeruli of NZB/W Fl mice when compared to the findings
at 32 weeks of age. The distribution and intensity of type IV
collagen, laminin, and HSPG in kidneys of NZBIW Fl mice were
decreased by treatment with FR139317 (Fig. 2). Immunofiuores-
cence scores for type IV collagen, laminin and HSPG in the
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Fig. 1. Histological analysis showing pathological changes in glomendi of
NZB/WFI mice. Microphotographs showing PAS staining of glomeruli. A.
48-week-old NZB/W Fl mice treated without FR139317; B. 48-week-old
NZB/W Fl mice treated with FR139317. Magnification X200.
Table 4. Histological scores of NZBIW Fl mice by light microscopy
32 weeks 48 weeks
Glomeruli
Treated with FR139317 1.4 0.26u 2.0 032b
Untreated 2.4 0.42 3.6 0.44
Interstitium
Treated with FR139317 1.3 0.28a 2.2 0.24k'
Untreated 2.3 0.32 3.8 0.50
Values are means SE.
up < 0.05, b P < 0.01 compared with untreated mice
glomeruli of NZB/W Fl mice with or without FR13931 7 treat-
ment are shown in Table 5. Collagen types I and III were not
detected in the glomeruli of eight-week-old NZBIW Fl mice by
immunofluorescence microscopy. However, these collagens were
detected in the glomeruli of NZB/W Fl mice at 32 weeks of age,
and increased amounts were observed in the glomeruli and
interstitium as the nephritis progressed. The amounts of type I
and III collagens in the glomeruli and interstitium were decreased
by FR139317 administration (Fig. 3). Immunofluorescence scores
for type I and III collagens in the glomeruli and interstitium of
NZB/W Fl mice with or without FR139317 treatment are shown
in Table 6.
Fig. 2. Immunofluorescence microscopy of the glomerulus using rabbit
antibody to mouse type IV collagen. A. 48-week-old NZB/W Fl mice not
treated with FR139317 B. 48-week-old NZB/W Fl mice treated with
FR139317. Magnification X400.
Table 5. Immunofluorescence scores of type IV collagen, laminin, and
HSPG in glomeruli of NZB/W Fl mice
Treated with FR139317 Untreated
Type IV collagen
32 weeks 2.5 0.34a 3.8 0.32
48 weeks 3.3 0.46a 4.6 0.62
Laminin
32 weeks 2.6 0.36a 3.9 0.44
48 weeks 3.4 0.42a 4.6 0.58
HSPG
32 weeks 2.4 0,56a 3.6 0.48
48 weeks 3.3 0.50' 4.7 0.58
Values are means SE.
P < 0.01 compared with untreated mice
mRNA analysis
Figure 4 shows a Northern blot analysis of al(I) (A), al(III)
(B) and al(IV) (C) collagen chains, laminin Bi (D) and B2 (E)
chains, HSPG (F), and GAPDH (G) mRNA levels in renal tissues
of NZBIW Fl mice at 8, 32, and 48 weeks of age. Table 7 shows
the relative changes of mRNA for these proteins. The al(IV)
transcripts increased 2.8-fold by 32 weeks of age (P < 0.01) and
"
-
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Table 6. Immunofluorescence scores of type I and type III collagens in
glomeruli and interstitium of NZB/W Fl mice
Type I collagen
Age weeks 32 48
Type III collagen
32 48
Glomeruli
Treated group 0.7 032b 2.2 0.48" 0.5 022b 1.8 052b
Untreated group 2.5 0.48 3.4 0.68 2.4 0.42 3.0 0.60
Interstitium
Treated group 2.1 0.46a 2.3 0.42" 2.2 0.52a 2.3 0.58"
Untreated group 2.9 0.56 3.3 0.58 2.8 0.44 3.2 0.46
Values are means SE.
a P < 0.05, b P < 0.01 compared with untreated mice
al(IV) collagen chains, laminin Bi and B2 chains, HSPG,
MMP-1, -2, -3, and TIMP-1 in the kidney of NZBIW Fl mice
treated with or without FR139317 at 48 weeks of age. FR139317
attenuated the increased mRNA levels for those proteins (Tables
7 and 8). FR139317 did not affect mRNA levels for ECM compo-
nents, MMPs, and TIMP-1 in the kidney of NZW mice.
Discussion
Fig. 3. Immunofluorescence microscopy of the glomerulus using rabbit
antibody to rat type I collagen. A. 48-week-old NZB/W Fl mice treated
without FR139317; B. 48-week-old NZB/W Fl mice treated with
FR139317. Magnification x400.
6.8-fold by 48 weeks of age (P < 0.001) as compared to age-
matched untreated NZW mice. Laminin Bi and B2 chain and
HSPG mRNAs showed a similar expression pattern [32 weeks of
age, laminin Bi, 2.2-fold (P < 0.01); laminin B2, 2.0-fold (P <
0.01); HSPG, 2.1-fold (P < 0.01) and 48 weeks of age, laminin Bi,
5.2-fold (P < 0.001); laminin B2, 5.0-fold (P < 0.001); and HSPG,
6.0-fold (P < 0.001)]. The mRNA levels for al(I) and s1(IlI)
collagen chains increased similarly to al(IV) collagen chain,
laminin chains and HSPG [32 weeks of age, al(I), 3.0-fold (P <
0.01); al(III), 2.2-fold (P < 0.01); and 48 weeks of age, al(I),
6.6-fold (P < 0.001); and csl(IIl), 4.6-fold (P < 0.001)]. mRNA
levels for GAPDH showed little change in NZB/W Fl mice and
NZW mice regardless of FR139317 treatment. Figure 5 shows
Northern blots of mRNA for MMP-1, -2, -3, and TIMP-1 in the
kidney of untreated NZB/W Fl mice. Table 8 shows the relative
changes of mRNA for these proteins. mRNA levels for MMP-1,
-2, -3, and TIMP-1 increased significantly with the progression of
nephritis [32 weeks of age, MMP-1, 2.8-fold (P < 0.01); MMP-2,
1.6-fold (P < 0.05); MMP-3, 3.2-fold (P < 0.01); TIMP-1, 7.6-fold
(P < 0.001) and 48 weeks of age, MMP-1, 7.6-fold (P < 0.001);
MMP-2, 4.2-fold (P < 0.01); MMP-3, 8.2-fold (P < 0.001), and
TIMP-1, 15.2-fold (P < 0.001)]. Figure 6 shows the Northern blot
analysis of mRNA for ECM components including cd (I), al (III),
In the present study, we demonstrated that a specific ETA
receptor antagonist ameliorated lupus nephritis and abnormally
increased expression of mRNA for ECM components, MMPs,
and TIMP-1. Recently, some investigators reported that an inter-
leukin-6 receptor blocker, or anti-interleukin 10 antibody, ame-
liorated murine lupus nephritis [34, 35]. Benigni et al [8] showed
that the ETA receptor antagonist protects against injury in
remnant kidneys. However, little is known about the effect of ETA
receptor antagonist on the regulation of ECM component, MMPs
and TIMP-1 genes in kidney of lupus mice.
Some investigators reported that lupus mice became severely
hypertensive with the progression of nephritis [13, 36]. It was
suggested that a reduction of the glomeriilar filtration rate (GFR)
by immune complex deposition ought to increase blood pressure.
Kiberd showed that the GFR fell in NZB/W Fl mice with the
progression of nephritis [1, 12]. Our data coincided with them.
FR139317 reduced systemic blood pressure and ameliorated GFR
in NZBIW Fl mice. Since systemic hypertension has a negative
impact on renal disease progression [37, 38], the question arises
whether the beneficial effect was due to antihypertensive actions
of FR139317. Some effect on the local determinants of renal
injury may be assumed to explain the renoprotective effect of ETA
receptor blocking [39]. It is unclear whether FR139317 amelio-
rates intraglomerular capillary hypertension in lupus nephritis in
the present study. In the preliminary study, we examined whether
angiotensin converting enzyme inhibitor, enalapril, have a similar
beneficial effect on gene expression of ECM components, MMPs,
and TIMP-1 in lupus nephritis. Enalapril reduced systemic hyper-
tension, whereas it had little effect on gene expression of all these
proteins examined (Nakamura T, et al, unpublished data). There-
fore, the beneficial effect may not only be due to antihypertensive
actions of antagonizing ETA receptor. Since we showed that
FR139317 ameliorated the GFR in lupus mice, our data may be
due to secondary to improvement in renal hemodynamics rather
than to a direct effect on structural changes described. Chan et al
demonstrated that the other ETA receptor antagonist, BQ123, has
a protective effect in the acute renal failure model as assessed by
GFR [9].
Treated group Untreated group
al(IV) collagen
32 weeks 1.6 0.4" 2.8 0.6
48 weeks 2.4 06b 6.8 1.4
laminin BI
32 weeks 1.2 0.4' 2.2 0.4
48 weeks 1.8 0.6" 5.2 1.8
laminin B2
32 weeks 1.3 0.3' 2.0 0.6
48 weeks 1.8 08b 5.0 1.6
HSPG
32 weeks 1.2 0.3' 2.1 0.4
48 weeks 1.9 0.8'' 6.0 2.0
al(I) collagen
32 weeks 1.4 0.4" 3.0 0.9
48 weeks 2.8 0.8" 6.6 2.2
al(III) collagen
32 weeks 1.2 0.4k 2.2 0.6
48 weeks 1.9 06b 4.6 1.3
Proliferation of intrinsic glomerular mesangial cells as well as
expansion of the mesangial extracellular matrix (ECM) are cen-
tral features of numerous glomerular diseases including lupus
nephritis. These processes play a pivotal role in the development
of glomerular sclerosis and renal failure [401. Given the complex
composition of the ECM, it is postulated that an extensive
spectrum of MMPs and TIMP-1 is involved in the turnover of the
ECM, particularly within the glomerular mesangium. The accu-
mulation of ECM results from a balance between synthetic and
degradative processes. The rate of ECM degradation probably
correlates with the relative levels of MMPs and TIMP. Our data
suggest that the enhanced expression of mRNA for ECM com-
ponents, MMPs, and TIMP-1 may contribute to the evolution of
renal injury in lupus nephritis. We previously demonstrated that
the renal concentrations of ET-1, ETA and ETB receptor mRNAs
increased significantly with age in NZB/W Fl mice and that those
Fig. 4. Northern blot analysis of al(I) (A),
al(III) (B), al(IV) (C) collagen chains, laminin
B] (D) and B2 (E) chains, HSPG (F), and
GAPDH (G) mRNA in renal tissues of NZBIW
Fl mice. Total cellular RNA (20 pg/lane) was
extracted from kidneys of 10 mice individually
at each time point and electrophoresed through
a 0.7% agarose gel containing formaldehyde,
and was then transferred to GeneScreen filters.
Lane 1, 8-weeks-old; lane 2, 32-weeks-old; lane
3, 48-weeks-old. One representative experiment
is shown.
of ET-3 mRNA did not change throughout the experimental
period [5].
A selective high-affinity ET receptor is the A receptor [41]. A
less selective ETB receptor has been identified [42]. The ETA
receptor mediates vasoconstriction and smooth muscle cell pro-
liferation, while the function of the ETB receptor is not fully
defined [43]. A role for enhanced endothelin expression in renal
disease progression is suggested by recent evidence of mesangial
cell proliferation and ECM protein synthesis in response to
endothelin [43, 44]. ETA receptor-linked phosphoinositide hydro-
lysis acts as the signal event for up-regulating phospholipase
C-mediated c-fos and c-myc oncogenes [45, 46]. These intracellu-
lar events are consistently associated with cell proliferation [47].
Proliferating cell nuclear antigen (PCNA) is an intranuclear
polypeptide whose expression and synthesis is linked to cell
proliferation [48]. We previously reported that NZB/W Fl mice
showed with age a significant increase of mRNA for PCNA [49].
We also recognized that mRNA for c-myc, c-fos, and c-jun
increased significantly with age in the kidneys of NZB/W Fl mice
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al(I) al(llI) al(IV)
Table 7. Relative changes in mRNA levels for al(IV) collagen chain,
laminin Bi and B2 chains, HSPG, al(I) and al(III) collagen chains in
the kidneys of NZB/W Fl mice treated with or without FR139317
MMP-1 MMP-2
Fig. 5. Northern blot analysis of MMP-l (A), MMP-2 (B), MMP-3 (C) and
TIMP-l (D) mRNA in renal tissues of NZBIW Fl mice. Lane 1, 8-weeks-
old; lane 2, 32-weeks-old; and lane 3, 48-weeks-old.Values are expressed as optical density units relative to the specific
mRNA levels observed in mRNA from untreated NZW control mice.
Values are means SE.
ap < 0.05, "P < 0.01 for untreated NZB/W Fl mice compared with
FR139317-treated NZB/W Fl mice
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Table 8. Relative changes in mRNA levels for MMP-1, MMP-2, MMP-3
and TIMP-l in the kidneys of NZB/W Fl mice treated with or without
FR139317
Treated group Untreated group
MMP-l
32 weeks 1.4 04b 2.8 0.6
48 weeks 2.4 j0h 7.6 2.2
MMP-2
32 weeks 1.2 0.2 1.6 0.4
48 weeks 1.8 08b 4.2 2.2
MMP-3
32 weeks 1.7 06b 3.2 0.8
48 weeks 2.8 0.8k 8.2 2.6
TIMP-1
32 weeks 2.6 o.gt 7.6 2.2
48 weeks 4.0 18b 15.2 4.8
Values are expressed as optical density units relative to the specific
mRNA levels observed in mRNA from untreated NZW control mice.
Values are means SE.
aP C oo, b P C 0.01 for untreated NZB/W Fl mice compared with
FR139317-treated NZB/W Fl mice
and that FR139317 suppressed the up-regulation of these proto-
oncogenes and PCNA expression in NZB/W Fl mice (Nakamura
T, et al, unpublished data). We previously reported that mRNA
levels for growth factors including platelet-derived growth factor
(PDGF), transforming growth factor (TGF)-f3, are increased
markedly with age in kidneys of NZB/W Fl mice [49, 50]. TGF-
and TNF-a have been shown to stimulate ET-1 mRNA and
protein in glomerular cells [51, 52]. Recently, Kohno et al [53]
reported that ET-1 production is increased by PDGF in mesangial
cells and that PDGF stimulate mitogenesis of these cells, at least
in part, by increasing endogenous ET-1 production. These growth
factors may lead to increased ET-1 synthesis in ETA receptor
activation. We recognized that levels of mRNA for these growth
factors in kidneys of NZB/W Fl mice are suppressed by treatment
with FR139317 (Nakamura T, et al, unpublished data). Therefore,
it may be speculated that blocking ETA receptors would limit the
biological consequences of growth factor-induced up-regulation
of genes encoding ECM components [54], thereby reducing a
major component of glomerular sclerosis [55]. Given the fact that
the ETB receptor mRNA is expressed in glomeruli [56, 57], the
potential role of ET receptor antagonist in suppressing the
progression of lupus nephritis cannot be excluded. In a prelimi-
nary study, however, we recognized that the ET receptor antag-
onist did not ameliorate lupus nephritis or abnormally regulated
ECM gene expression (Nakamura T, et al, unpublished data).
Therefore, the ETA receptor antagonist specifically reduced lupus
nephritis.
In summary, severe lupus nephritis is reversed by the selective
ETA receptor antagonist, FR139317, by significantly improving
abnormally regulated ECM gene expression. Our data may be of
clinical importance, as it suggests a possible therapeutic approach
for retarding the progression of lupus nephritis.
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